Recently, Elodie Bosc et al. presented a definitive perspective on caspase-2-specific inhibitors for the treatment of MASLD, while their studies exposed that 3-(S)-neopentyl proline (LJ3a) and 6-methyl-tetrahydro-isoquinoline (LJ2a) inhibited caspase-2-mediated activation of SREBP2 [63]. This evidence concerns the gene CASP2 and metabolic dysfunction-associated steatotic liver disease.